74.92
price down icon0.25%   -0.19
pre-market  Pre-mercato:  74.08   -0.84   -1.12%
loading
Precedente Chiudi:
$75.11
Aprire:
$74.41
Volume 24 ore:
2.34M
Relative Volume:
0.54
Capitalizzazione di mercato:
$44.68B
Reddito:
$5.54B
Utile/perdita netta:
$4.18B
Rapporto P/E:
10.70
EPS:
7
Flusso di cassa netto:
$259.90M
1 W Prestazione:
-1.78%
1M Prestazione:
+8.02%
6M Prestazione:
+13.95%
1 anno Prestazione:
-11.95%
Intervallo 1D:
Value
$74.25
$75.36
Intervallo di 1 settimana:
Value
$74.15
$77.12
Portata 52W:
Value
$58.93
$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name
Nome
Edwards Lifesciences Corp
Name
Telefono
(949) 250-2500
Name
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Name
Dipendente
15,800
Name
Cinguettio
@edwardslifesci
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
EW's Discussions on Twitter

Confronta EW con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Medical Devices icon
EW
Edwards Lifesciences Corp
74.92 44.68B 5.54B 4.18B 259.90M 7.00
Medical Devices icon
ABT
Abbott Laboratories
133.06 227.05B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
104.12 152.00B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
377.52 139.34B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
82.32 108.50B 33.20B 4.26B 5.47B 3.29

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-24 Aggiornamento Piper Sandler Neutral → Overweight
2025-01-30 Aggiornamento Stifel Hold → Buy
2025-01-16 Downgrade Wolfe Research Peer Perform → Underperform
2024-12-16 Aggiornamento BofA Securities Neutral → Buy
2024-10-11 Ripresa Morgan Stanley Equal-Weight
2024-09-18 Downgrade Jefferies Buy → Hold
2024-07-31 Aggiornamento Daiwa Securities Neutral → Outperform
2024-07-29 Aggiornamento Wolfe Research Underperform → Peer Perform
2024-07-25 Downgrade BofA Securities Buy → Neutral
2024-07-25 Downgrade JP Morgan Overweight → Neutral
2024-07-25 Downgrade Robert W. Baird Outperform → Neutral
2024-07-25 Downgrade TD Cowen Buy → Hold
2024-07-25 Downgrade Truist Buy → Hold
2024-05-30 Iniziato Goldman Buy
2024-05-22 Aggiornamento Citigroup Neutral → Buy
2024-05-14 Aggiornamento Deutsche Bank Hold → Buy
2024-03-07 Aggiornamento BofA Securities Neutral → Buy
2024-02-02 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-01-04 Downgrade Evercore ISI Outperform → In-line
2023-12-11 Downgrade Citigroup Buy → Neutral
2023-11-28 Downgrade Wolfe Research Peer Perform → Underperform
2023-09-26 Aggiornamento Oppenheimer Perform → Outperform
2023-07-19 Iniziato Robert W. Baird Outperform
2023-05-30 Ripresa Morgan Stanley Overweight
2023-03-29 Iniziato UBS Neutral
2023-03-08 Downgrade Wells Fargo Overweight → Equal Weight
2023-02-06 Downgrade Raymond James Outperform → Mkt Perform
2023-01-31 Downgrade Bernstein Outperform → Underperform
2023-01-30 Downgrade Piper Sandler Overweight → Neutral
2022-12-06 Downgrade Stifel Buy → Hold
2022-10-28 Downgrade Oppenheimer Outperform → Perform
2022-10-26 Iniziato Mizuho Buy
2022-10-18 Iniziato Barclays Overweight
2022-10-12 Iniziato Jefferies Buy
2022-07-29 Downgrade Canaccord Genuity Buy → Hold
2022-04-13 Iniziato Truist Buy
2022-04-06 Iniziato Wolfe Research Outperform
2022-03-16 Aggiornamento Bernstein Mkt Perform → Outperform
2022-03-02 Ripresa BofA Securities Neutral
2022-02-02 Aggiornamento UBS Neutral → Buy
2022-01-27 Reiterato Citigroup Buy
2022-01-27 Reiterato Evercore ISI Outperform
2022-01-27 Reiterato Raymond James Outperform
2022-01-27 Reiterato Stifel Buy
2022-01-27 Reiterato UBS Neutral
2021-12-17 Aggiornamento JP Morgan Neutral → Overweight
2021-12-15 Aggiornamento Citigroup Neutral → Buy
2021-12-10 Iniziato RBC Capital Mkts Outperform
2021-12-06 Aggiornamento Wells Fargo Equal Weight → Overweight
2021-07-30 Reiterato Canaccord Genuity Buy
2021-07-30 Reiterato Deutsche Bank Hold
2021-07-30 Reiterato Jefferies Buy
2021-07-30 Reiterato Morgan Stanley Overweight
2021-07-30 Reiterato Oppenheimer Outperform
2021-07-30 Reiterato Stifel Buy
2021-07-30 Reiterato UBS Neutral
2021-07-30 Reiterato Wells Fargo Equal Weight
2021-05-25 Iniziato Barclays Overweight
2021-04-15 Iniziato Atlantic Equities Neutral
2021-04-05 Aggiornamento Evercore ISI In-line → Outperform
2020-12-16 Downgrade Citigroup Buy → Neutral
2020-12-11 Reiterato Canaccord Genuity Buy
2020-09-11 Iniziato Wolfe Research Underperform
2020-04-28 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-03-05 Iniziato Citigroup Buy
2020-02-13 Iniziato Goldman Neutral
2020-02-06 Ripresa BTIG Research Neutral
2020-01-10 Iniziato Oppenheimer Outperform
2020-01-02 Downgrade Evercore ISI Outperform → In-line
2019-10-24 Reiterato Canaccord Genuity Buy
2019-09-23 Iniziato Piper Jaffray Overweight
2019-07-24 Reiterato BofA/Merrill Buy
2019-03-18 Reiterato Canaccord Genuity Buy
2019-01-18 Aggiornamento BofA/Merrill Neutral → Buy
2019-01-03 Iniziato Deutsche Bank Hold
2018-11-28 Iniziato UBS Neutral
2018-10-16 Iniziato Barclays Underweight
2018-10-02 Downgrade BofA/Merrill Buy → Neutral
2018-10-02 Downgrade Guggenheim Buy → Neutral
Mostra tutto

Edwards Lifesciences Corp Borsa (EW) Ultime notizie

pulisher
12:17 PM

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus

12:17 PM
pulisher
May 06, 2025

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

May 06, 2025
pulisher
May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025
pulisher
May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

FDA Approves First-Ever TAVR Treatment for Asymptomatic Aortic Stenosis Patients - Stock Titan

May 01, 2025
pulisher
Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025
pulisher
Apr 28, 2025

Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq

Apr 28, 2025
pulisher
Apr 26, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, T - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Piper Sandler raises Edwards Lifesciences stock to Overweight - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardi - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Reports Strong Q1 Growth - TipRanks

Apr 24, 2025
pulisher
Apr 23, 2025

Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Reports First Quarter Results - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan

Apr 23, 2025
pulisher
Apr 21, 2025

EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue - BioSpace

Apr 21, 2025
pulisher
Apr 19, 2025

Lobbying Update: $350,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq

Apr 19, 2025
pulisher
Apr 18, 2025

Edwards touts 8-year data for Resilia valve tissue - MassDevice

Apr 18, 2025
pulisher
Apr 18, 2025

Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan

Apr 18, 2025
pulisher
Apr 17, 2025

Is Edwards Lifesciences Gaining or Losing Market Support?Edwards Lifesciences (NYSE:EW) - Benzinga

Apr 17, 2025
pulisher
Apr 17, 2025

Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN

Apr 17, 2025

Edwards Lifesciences Corp Azioni (EW) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$81.53
price up icon 1.57%
$67.09
price down icon 3.29%
medical_devices STE
$222.45
price down icon 0.82%
medical_devices PHG
$24.09
price down icon 6.05%
medical_devices ZBH
$92.27
price up icon 1.98%
Capitalizzazione:     |  Volume (24 ore):